BACKGROUND: Obesity and obesity-associated type 2 diabetes mellitus (T2DM) are frequently related to a low-grade chronic inflammatory state, which increases the risk of developing cardiovascular diseases. The aim of the present work was to evaluate the effect of obesity and T2DM on the concentrations of pro-inflammatory factors and to study the effect of weight loss after Roux-en-Y gastric bypass (RYGBP). METHODS: Plasma concentrations of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), serum amyloid A (SAA) and sialic acid (SA) were measured in 25 female volunteers. The concentrations of these cytokines were determined in 14 female obese patients before and after weight loss following RYGBP. Additionally, visceral adipose tissue (VAT) obtained from 15 females was used to quantify expression levels of MCP-1 and CD68 by Real-Time PCR. RESULTS: Both obese normoglycemic (NG) and T2DM groups exhibited significantly higher MCP-1 (P < 0.05), TNF-alpha (P < 0.01), SAA (P < 0.05) and SA (P < 0.05) concentrations, compared to the lean group. No differences were found between obese NG and obese T2DM subjects. A significant positive correlation was found between body fat percentage (BF) and all inflammatory markers (P < 0.05) studied. MCP-1 expression levels in VAT were upregulated in obese NG (P = 0.008) and obese T2DM (P = 0.032) patients compared to lean subjects, but no additional detrimental effect of T2DM was observed between both obese groups. After weight loss, SAA (P < 0.001) and SA (P < 0.05) concentrations diminished, whereas circulating levels of MCP-1 showed a tendency to decrease (P = 0.093) and TNF-alpha did not change. CONCLUSION: The present findings suggest that elevated pro-inflammatory cytokine levels found in obese patients relate mainly to obesity rather than to T2DM. Moreover, surgery-induced weight loss reduces circulating concentrations of key pro-inflammatory factors, which contribute to the improvement in the cardiovascular co-morbidity following excess weight loss.
BACKGROUND:Obesity and obesity-associated type 2 diabetes mellitus (T2DM) are frequently related to a low-grade chronic inflammatory state, which increases the risk of developing cardiovascular diseases. The aim of the present work was to evaluate the effect of obesity and T2DM on the concentrations of pro-inflammatory factors and to study the effect of weight loss after Roux-en-Y gastric bypass (RYGBP). METHODS: Plasma concentrations of monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), serum amyloid A (SAA) and sialic acid (SA) were measured in 25 female volunteers. The concentrations of these cytokines were determined in 14 female obesepatients before and after weight loss following RYGBP. Additionally, visceral adipose tissue (VAT) obtained from 15 females was used to quantify expression levels of MCP-1 and CD68 by Real-Time PCR. RESULTS: Both obese normoglycemic (NG) and T2DM groups exhibited significantly higher MCP-1 (P < 0.05), TNF-alpha (P < 0.01), SAA (P < 0.05) and SA (P < 0.05) concentrations, compared to the lean group. No differences were found between obese NG and obese T2DM subjects. A significant positive correlation was found between body fat percentage (BF) and all inflammatory markers (P < 0.05) studied. MCP-1 expression levels in VAT were upregulated in obese NG (P = 0.008) and obese T2DM (P = 0.032) patients compared to lean subjects, but no additional detrimental effect of T2DM was observed between both obese groups. After weight loss, SAA (P < 0.001) and SA (P < 0.05) concentrations diminished, whereas circulating levels of MCP-1 showed a tendency to decrease (P = 0.093) and TNF-alpha did not change. CONCLUSION: The present findings suggest that elevated pro-inflammatory cytokine levels found in obesepatients relate mainly to obesity rather than to T2DM. Moreover, surgery-induced weight loss reduces circulating concentrations of key pro-inflammatory factors, which contribute to the improvement in the cardiovascular co-morbidity following excess weight loss.
Authors: Sai Krupa Das; Susan B Roberts; Joseph J Kehayias; Jack Wang; L K George Hsu; Scott A Shikora; Edward Saltzman; Megan A McCrory Journal: Am J Physiol Endocrinol Metab Date: 2003-02-25 Impact factor: 4.310
Authors: J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: S Müller; S Martin; W Koenig; P Hanifi-Moghaddam; W Rathmann; B Haastert; G Giani; T Illig; B Thorand; H Kolb Journal: Diabetologia Date: 2002-05-08 Impact factor: 10.122
Authors: Aina S Lihn; Jens M Bruun; Gengsheng He; Steen B Pedersen; Peter F Jensen; Bjørn Richelsen Journal: Mol Cell Endocrinol Date: 2004-04-30 Impact factor: 4.102
Authors: Javier Gómez-Ambrosi; Victoria Catalán; Alberto Diez-Caballero; L Alfonso Martinez-Cruz; María J Gil; Jesús García-Foncillas; Javier A Cienfuegos; Javier Salvador; José M Mato; Gema Frühbeck Journal: FASEB J Date: 2003-11-20 Impact factor: 5.191
Authors: Wojciech Szczęsny; Magdalena Kuligowska-Prusińska; Stanisław Dąbrowiecki; Jakub Szmytkowski; Adrian Reśliński; Maciej Słupski Journal: J Zhejiang Univ Sci B Date: 2018 Jan. Impact factor: 3.066
Authors: Victoria Catalán; Javier Gómez-Ambrosi; Amaia Rodríguez; Beatriz Ramírez; Fernando Rotellar; Victor Valentí; Camilo Silva; María J Gil; José Manuel Fernández-Real; Javier Salvador; Gema Frühbeck Journal: Mol Med Date: 2011-07-05 Impact factor: 6.354
Authors: J M Gallego-Escuredo; J Gómez-Ambrosi; V Catalan; P Domingo; M Giralt; G Frühbeck; F Villarroya Journal: Int J Obes (Lond) Date: 2014-05-12 Impact factor: 5.095
Authors: David M Mutch; Jens C Fuhrmann; Dietrich Rein; Jan C Wiemer; Jean-Luc Bouillot; Christine Poitou; Karine Clément Journal: PLoS One Date: 2009-11-19 Impact factor: 3.240
Authors: Evros K Vassiliou; Andres Gonzalez; Carlos Garcia; James H Tadros; Goutam Chakraborty; Jeffrey H Toney Journal: Lipids Health Dis Date: 2009-06-26 Impact factor: 3.876